Literature DB >> 10235544

Correlation of VEGF expression by leukocytes with the growth and regression of blood vessels in the rat cornea.

J L Edelman1, M R Castro, Y Wen.   

Abstract

PURPOSE: To determine the temporal and spatial relationships between neovascularization and basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) mRNA and protein expression in the rat cornea after cautery with silver nitrate.
METHODS: In female Sprague-Dawley rats, a silver nitrate applicator was placed on the central cornea to elicit circumferential angiogenesis, and blood vessel growth was quantified by digital image analysis of corneal flat-mounts. Total RNA or protein was extracted from whole corneas until 1 week after cautery, and bFGF and VEGF mRNA and protein levels were determined by reverse transcription-polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA). To localize VEGF mRNA and protein, paraformaldehyde-fixed and paraffin-embedded histologic cross sections of corneas were examined by in situ hybridization and immunohistochemistry. Macrophages were identified by ED2 immunohistochemistry. To examine the regulation of VEGF, rats were treated with dexamethasone (0.5 mg/kg per day) and hyperoxia (70% O2).
RESULTS: The neovascular response progresses in three phases: (1) a nonproliferative phase preceding vessel growth (< or = 48 hours after cautery); (2) a proliferative phase with maximal growth rate between 3 and 4 days; and (3) a regressive phase (day 7) with a decrease in vessel density accompanying the completion of vessel elongation. In corneas after cautery, bFGF mRNA expression was unchanged, and bFGF protein concentration decreaseed by 97% after 24 hours and returned to control levels by day 7. In contrast, VEGF164 and VEGF188 mRNA splice variants and protein peaked 48 hours after cautery, remained elevated 4 days after cautery, and decreased to near baseline by day 7. The peak concentration of VEGF in the cornea at 48 hours was calculated to be 720 pM, which is sufficient to evoke a functional response. In situ hybridization and immunohistochemistry showed VEGF expressed initially in neutrophils (24 - 48 hours) and subsequently in macrophages (4 days) adjacent to the cautery site. Treatment with either dexamethasone or systemic hyperoxia inhibited both neovascularization and the increase in VEGF expression. Dexamethasone inhibited 27% of cautery-induced VEGF upregulation at 24 hours and 23% at 48 hours, hyperoxia inhibited 32% at 24 hours and 43% at 48 hours, and combined treatment with both dexamethasone and hyperoxia had an additive effect (56% inhibition at 24 hours).
CONCLUSIONS: VEGF production by leukocytes correlates temporally and spatially with cautery-induced angiogenesis in the rat cornea. Both inflammatory products and hypoxia appear to sufficiently increase VEGF expression near the cautery lesion to increase vascular permeability of limbal vessels and induce endothelial cell migration and proliferation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10235544

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  24 in total

1.  Features of corneal neovascularization and lymphangiogenesis induced by different etiological factors in mice.

Authors:  Weiyun Shi; Chunping Ming; Juncai Liu; Ting Wang; Hua Gao
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-07-17       Impact factor: 3.117

2.  P450 in the angiogenesis affair: the unusual suspect.

Authors:  Alexander V Ljubimov; Maria B Grant
Journal:  Am J Pathol       Date:  2005-02       Impact factor: 4.307

3.  Loss of tumor necrosis factor alpha potentiates transforming growth factor beta-mediated pathogenic tissue response during wound healing.

Authors:  Shizuya Saika; Kazuo Ikeda; Osamu Yamanaka; Kathleen C Flanders; Yuka Okada; Takeshi Miyamoto; Ai Kitano; Akira Ooshima; Yuji Nakajima; Yoshitaka Ohnishi; Winston W-Y Kao
Journal:  Am J Pathol       Date:  2006-06       Impact factor: 4.307

4.  Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin).

Authors:  Roberta P A Manzano; Gholam A Peyman; Palwasha Khan; Petros E Carvounis; Muhamet Kivilcim; Min Ren; Jonathan C Lake; Patricia Chévez-Barrios
Journal:  Br J Ophthalmol       Date:  2006-12-19       Impact factor: 4.638

5.  Anti-TNF-alpha antibody Infliximab and glucocorticoids reduce serum vascular endothelial growth factor levels in patients with rheumatoid arthritis: a pilot study.

Authors:  Johannes Strunk; Elisabeth Bundke; Uwe Lange
Journal:  Rheumatol Int       Date:  2005-07-06       Impact factor: 2.631

6.  Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis.

Authors:  M Zheng; S Deshpande; S Lee; N Ferrara; B T Rouse
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

Review 7.  Role of the endothelium in inflammatory bowel diseases.

Authors:  Walter E Cromer; J Michael Mathis; Daniel N Granger; Ganta V Chaitanya; J Steven Alexander
Journal:  World J Gastroenterol       Date:  2011-02-07       Impact factor: 5.742

Review 8.  Current and emerging therapies for corneal neovascularization.

Authors:  Danial Roshandel; Medi Eslani; Alireza Baradaran-Rafii; Albert Y Cheung; Khaliq Kurji; Sayena Jabbehdari; Alejandra Maiz; Setareh Jalali; Ali R Djalilian; Edward J Holland
Journal:  Ocul Surf       Date:  2018-06-20       Impact factor: 5.033

9.  Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators.

Authors:  Yiping Jin; Makoto Arita; Qiang Zhang; Daniel R Saban; Sunil K Chauhan; Nan Chiang; Charles N Serhan; Reza Dana
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-04-30       Impact factor: 4.799

10.  Corneal neovascularization during experimental fungal keratitis.

Authors:  Xiaoyong Yuan; Kirk R Wilhelmus
Journal:  Mol Vis       Date:  2009-09-29       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.